EUVIMEDEUVIMED entdecken
Crossref

Early Nationwide Prescribing of Ultrahigh‐Dose Methylcobalamin for Amyotrophic Lateral Sclerosis in Japan: Comparison With Established Therapies

Takuya Omura, Takahiro Kamihara

Neurology and Clinical Neuroscience · 01.11.2026

DOI: 10.1002/ncn3.70188 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neurology and Clinical Neuroscience, online erschienen am 01.11.2026. Verfasst von Takuya Omura und 1 weiteren Autor:innen. Die Arbeit nennt 20 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Treatment options for amyotrophic lateral sclerosis remain limited, and the uptake of newly approved therapies in routine care is poorly characterized. Japan launched ultrahigh‐dose intramuscular methylcobalamin for amyotrophic lateral sclerosis in November 2024.

Aim

To describe early nationwide methylcobalamin prescription quantities and compare their scale with established amyotrophic lateral sclerosis therapies.

Methods

We analyzed fiscal year 2024 aggregate prescription quantities from Japan's National Database of Health Insurance Claims and Specific Health Checkups Open Data. Quantities from January through March 2025 were converted to monthly regimen equivalents based on approved dosing schedules. We compared methylcobalamin with oral edaravone and riluzole. We classified prefectures according to whether a positive prescribing quantity was directly disclosed.

Results

Methylcobalamin prescribing increased from 1142.4 monthly regimen equivalents in January to 1755.5 in March (+53.7%). The calendar‐day‐adjusted increase from February to March was 3.2%. In March, the standardized methylcobalamin volume was 49.5% of oral edaravone volume calculated using maintenance dosing, and at most 35.9% of the total riluzole volume. During fiscal year 2024, positive methylcobalamin quantities were directly reported in 32 of 47 prefectures. The remaining 15 could not be classified because of suppressed cells.

Conclusion

By March 2025, approximately 4 months after launch, ultrahigh‐dose methylcobalamin prescribing had reached nearly half the oral edaravone maintenance‐regimen‐equivalent volume. These national quantity‐based estimates provide an early benchmark for evaluating subsequent prescribing as more national claims data become available.

Zitieren

APA

Omura, T., & Kamihara, T. (2026). Early Nationwide Prescribing of Ultrahigh‐Dose Methylcobalamin for Amyotrophic Lateral Sclerosis in Japan: Comparison With Established Therapies. Neurology and Clinical Neuroscience. https://doi.org/10.1002/ncn3.70188

Vancouver

Omura T, Kamihara T. Early Nationwide Prescribing of Ultrahigh‐Dose Methylcobalamin for Amyotrophic Lateral Sclerosis in Japan: Comparison With Established Therapies. Neurology and Clinical Neuroscience. 2026. doi:10.1002/ncn3.70188

BibTeX
@article{Omura2026,
  author = {Omura, Takuya and Kamihara, Takahiro},
  title = {Early Nationwide Prescribing of Ultrahigh‐Dose Methylcobalamin for Amyotrophic Lateral Sclerosis in Japan: Comparison With Established Therapies},
  journal = {Neurology and Clinical Neuroscience},
  year = {2026},
  doi = {10.1002/ncn3.70188}
}
Kostenlos starten →